Leonard Krupnik, Jonathan Avaro, Marianne Liebi, Neda Iranpour Anaraki, Joachim Kohlbrecher, Alla Sologubenko, Stephan Handschin, Andrzej J Rzepiela, Christian Appel, Tiberiu Totu, Clement E Blanchet, Amy E Barton Alston, Reinaldo Digigow, Erik Philipp, Beat Flühmann, Bruno F B Silva, Antonia Neels, Peter Wick
Intravenous (IV) iron-carbohydrate complexes are widely used nanoparticles (NPs) to treat iron deficiency anaemia, often associated with medical conditions such as chronic kidney disease, heart failure and various inflammatory conditions. Even though a plethora of physicochemical characterisation data and clinical studies are available for these products, evidence-based correlation between physicochemical properties of iron-carbohydrate complexes and clinical outcome has not fully been elucidated yet. Studies on other metal oxide NPs suggest that early interactions between NPs and blood upon IV injection are key to understanding how differences in physicochemical characteristics of iron-carbohydrate complexes cause variance in clinical outcomes...
March 2, 2024: Journal of Controlled Release